
NASDAQHealthcareBiotechnology
Latest quote
$39.29
−$0.57 · -1.43%
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Previous close
$39.29
−$0.57 · -1.43%
Regular session · ET · Market data may be delayed.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $39.29
52-week range
Current $39.29
Regular session · ET · Market data may be delayed.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Day range
Current $39.29
52-week range
Current $39.29
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$54.50
38.71% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI21.04M0.22%9.64B USD0.35%$140.18-2.73%
iShares Russell 2000 ETFIWM20.62M0.03%71.54B USD0.19%$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI18.98M0.00%689.3B USD0.03%$340.02-3.52%
Vanguard Extended Market ETFVXF8.36M0.01%30.2B USD0.05%$211.44-3.21%
Vanguard Russell 2000 ETFVTWO4.83M0.03%16.8B USD0.06%$103.76-2.76%
iShares Russell 2000 Growth ETFIWO4.49M0.03%12.73B USD0.24%$320.43-3.57%
Schwab U.S. Small-Cap ETFSCHA3.71M0.02%20.45B USD0.03%$30.51-2.83%
iShares Russell 2000 Value ETFIWN3.02M0.02%13.05B USD0.24%$198.84-2.08%
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
Vanguard Russell 2000 ETFVTWO
iShares Russell 2000 Growth ETFIWO
Schwab U.S. Small-Cap ETFSCHA
iShares Russell 2000 Value ETFIWNAI-generated and delayed market data for informational and educational purposes only. Not investment advice.